| Literature DB >> 31601012 |
Ke Li1,2, Shuying Li3,4,5, Di Wang6,7,8, Xiaoxia Li9, Xingkang Wu10,11, Xiaojie Liu12,13, Guanhua Du14, Xianrong Li15,16, Xuemei Qin17,18, Yuguang Du19.
Abstract
Astragalus radix (radix) have been frequently used for clinical application in China, and the herb residues of radix turn out to be a waste of resources. To escape from this, the medicine value of radix herb residues is mined in this article. We isolated hemicellulose polysaccharide AX-I-3b from radix herb residues by fractional extraction. Monosaccharide-composition analysis revealed that AX-I-3b consisted of arabinose, xylose, and glucose with a molar ratio of 10.4:79.3:1.1. Methylation, NMR and FT-IR analyses showed that AX-I-3b monosaccharide residue was linked as follows: →2,3,4)-β-d-Xylp-(1→, →4)-β-d-Arap-(1→, →4)-β-d-Glcp-(1→. Then, we found that AX-I-3b exhibited antitumor activity against lung cancer in vitro and vivo through MTT assay and xenograft tumor model. Mechanistically, AX-I-3b induced apoptosis in lung cancer cells and xenograft tumors, which is evidenced by the up-regulation of p53, Bax and cleaved caspase-3, and the down-regulation of Bcl-2. Moreover, AX-I-3b synergistically improved the therapeutic ability of cisplatin in xenograft tumors model. Furthermore, AX-I-3b treatment effectively improved the immune organ index, the percentage of spleen lymphocyte subsets and serum cytokine levels in lung cancer mice, supporting that AX-I-3b showed immunomodulatory activity. In conclusion, our results identified AX-I-3b as an antitumor and immunomodulatory agent, providing a new insight into the reutilization of radix herb residue.Entities:
Keywords: Astragalus radix herb residue; antitumor; characterization; hemicellulose polysaccharide; immunomodulatory
Mesh:
Substances:
Year: 2019 PMID: 31601012 PMCID: PMC6833037 DOI: 10.3390/molecules24203644
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chromatography of AX-I-3b on DEAE-cellulose 52 Column (A) and on SepHacryl S-400 HR gel column (B).
Figure 2High-performance gel chromatogram of AX-I-3b. The monosaccharide composition of AX-I-3b was analyzed by GC-MS. The total-ion current diagram is shown in Figure 3. Comparing to the retention times of the monosaccharide references, the polysaccharide AX-I-3b contained arabinose (Ara; retention time tR = 25.51 min), xylose (Xyl; tR = 26.25 min), and glucose (Glc; tR = 33.41 min), at a molar ratio of 10.4:79.3:1.1 (Supplementary Table S2).
Figure 4FT-IR spectrum of AX-I-3b.
Figure 5GC-MS total-ion chromatogram of AX-I-3b methylation.
Results of methylation analysis of AX-I-3b.
| Peak No. | Methylated | Linkage Types | Molar Ratio |
|---|---|---|---|
|
| Xyl- | →2,3,4)- | 82.81 |
|
| 2,3-Me2-Ara | →4)- | 9.23 |
|
| 2,3,6-Me4-Glc | →4)- | 1.14 |
Figure 61H-NMR (A), 13C-NMR (B), HMBC (C), and HSQC (D) Spectra of AX-I-3b.
Chemical shifts of glycosyl 1H and 13C in AX-I-3b.
| Residues |
| |||||
|---|---|---|---|---|---|---|
| 1-H/C1 | 2-H/C2 | 3-H/C3 | 4-H/C4 | 5-H/C5 | 6-H/C6 | |
| →4)- | 4.28/102.0 | 3.87/74.2 | 3.66/75.8 | 3.05/80.2 | 3.73/63.7 | -/- |
| →2,3,4)- | 4.78/102.0 | 3.05/73.1 | 3.27/74.5 | 3.87/75.9 | 3.42/62.9 | -/- |
| →4)- | 5.00/100.6 | 3.73/71.9 | 3.87/73.1 | 4.05/71.9 | 3.50/74.5 | 3.73/60.8 |
Figure 7AX-I-3b inhibits tumor growth of Lewis lung cancer in mice. (A) The transplanted tumors of Lewis lung cancer mice treated with indicated compounds; (B) The growth inhibition rate of indicated compounds against transplanted tumors; (C) Tumor pathological section of transplanted tumors (stained with HE, ×400). Scale bars, 50 μm.
Figure 8AX-I-3b improved immunity of Lewis lung cancer mice. (A) AX-I-3b increased immune organ index in Lewis lung cancer mice; (B) AX-I-3b increased serum cytokines levels in Lewis lung cancer mice; (C) Distribution of T cell subsets in the spleen of Lewis lung cancer mice by flow cytometry; (D) The effect of AX-I-3b on the distribution of spleen T cell subsets; (E) The effect of AX-I-3b on the CD4+/CD8+. * p < 0.05 compared with groups without drug treatment; # p < 0.05 compared with groups treated with DDP (6 mg/mL).
Figure 9AX-I-3b induced apoptosis in tumor tissues. Data are shown as means ± SD. (n = 3). * p < 0.05 compared with the model group; # p < 0.05 compared with with the DDP group. (A) Western blot analysis of expression of apoptotic proteins in tumor tissues; (B) The expression of p53; (C) The expression of Bax; (D) The expression of Bcl-2; (E) The expression of caspase-3.
Figure 10Effect of AX-I-3b on A549 cells. (A) Effect of AX-I-3b on the cell viability of A549 cells; (B) The apoptosis detection of A549 cells induced by AX-I-3b; (C) Effect of AX-I-3b on apoptosis protein and anti-apoptotic protein expression in A549 cells by Western blot analysis. Values are means ± SD (n = 3). * p < 0.05, ** p < 0.01 and *** p < 0.001 as compared with the control.
Figure 11Immunomodulatory activity and potential anti-tumor mechanism of AX-I-3b.